MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to companies across all industries.
Business Model: B2B
Revenue: $75M
Employees: 201-500
Address: 7255 Woodmont Avenue
City: Bethesda
State: MD
Zip: 20814
Country: US
MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to companies across all industries. We provide a broad array of products intended to finance growth and manage working capital. As of January 2015, MidCap Financial has over $3 billion of commitments under management. Since our founding in 2008, we have been working with management teams and sponsors to deliver thoughtful and cost effective debt solutions. Companies need a lender that understands their business and has the creativity and flexibility to provide financing solutions that are suited to their needs. At MidCap Financial, our years of experience, strong balance sheet, and flexibility make us the lender of choice for companies across all stages of growth and complexity. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management agreement. Apollo Global Management is one of the world&s;s largest asset managers with over $160B of assets under management (as of January 2015), providing market leading industry expertise, market reach, and financing synergies.
Contact Phone:
+13017607600
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2015 | Quotient Biodiagnostics | Post-IPO Debt | 35M |
3/2017 | Fundation | Debt Financing | 35M |
3/2014 | Omeros | Post-IPO Debt | 32M |
6/2017 | Aziyo Biologics | Venture Round | 12M |
10/2022 | Surmodics | Post-IPO Debt | 125M |
6/2015 | BioDelivery Sciences | Post-IPO Debt | 20.7M |
5/2021 | Xtant Medical | Post-IPO Debt | 20M |
5/2012 | Stellar Pharmaceuticals Inc | Debt Financing | 6M |
4/2018 | The Credit Junction | Debt Financing | 150M |
8/2010 | Endocyte | Venture Round | 15M |
2/2018 | Partner Therapeutics | Series A | 60M |
9/2019 | Sight Sciences | Series D | 31M |
12/2015 | Spectranetics | Post-IPO Debt | 110M |
12/2013 | Quotient Biodiagnostics | Debt Financing | 15M |
5/2020 | Medexus Pharma | Post-IPO Debt | 0 |
1/2020 | Digital Reasoning | Series D | 0 |
12/2021 | Aterian | Post-IPO Debt | 50M |
12/2019 | Arboretum Investment Advisors, LLC. | Debt Financing | 25M |
10/2019 | Protagonist Therapeutics | Post-IPO Debt | 50M |
3/2013 | Theraclone Sciences | Debt Financing | 6M |
2/2018 | ZPower | Debt Financing | 25M |
5/2022 | TELA Bio | Post-IPO Debt | 50M |
4/2016 | IOU Financial | Post-IPO Debt | 50M |
12/2018 | Sonar Entertainment | Debt Financing | 121M |
3/2016 | Spectra7 Microsystems | Post-IPO Debt | 6.5M |
9/2016 | BioCryst Pharmaceuticals | Post-IPO Debt | 23M |
8/2021 | Unchained Labs | Debt Financing | 0 |
4/2015 | Staffing 360 Solutions | Post-IPO Debt | 28M |
7/2017 | Sarepta Therapeutics | Post-IPO Debt | 100M |
11/2022 | ViewRay | Post-IPO Debt | 125M |
10/2018 | Kashable | Debt Financing | 100M |
12/2013 | Apollo Endosurgery | Debt Financing | 50M |
8/2015 | Flexion Therapeutics | Post-IPO Debt | 30M |
12/2013 | Amicus Therapeutics | Post-IPO Debt | 10M |
4/2014 | Larimar Therapeutics | Debt Financing | 20M |
5/2016 | Intarcia Therapeutics | Debt Financing | 75M |
1/2022 | Forge Biologics | Debt Financing | 0 |
10/2022 | Carbon6 Technologies | Debt Financing | - |
9/2014 | Aventine Renewable Energy Holdings Inc | Debt Financing | 40M |
11/2021 | Upstack | Private Equity Round | 100M |
3/2019 | Organogenesis | Debt Financing | 100M |
2/2019 | BioCryst Pharmaceuticals | Post-IPO Debt | 100M |
10/2016 | Oxford Immunotec | Post-IPO Debt | 40M |
10/2022 | Carbon6 | Series A | 0 |
3/2021 | LendingPoint | Debt | 110M |
1/2018 | DNAnexus | Series E | 58M |
5/2019 | Gossamer Bio | Post-IPO Debt | 150M |
5/2022 | TELA Bio | Post-IPO Debt | 0 |
1/2022 | Forge Biologics | Debt Financing | 0 |
12/2021 | Aterian | Post-IPO Debt | 0 |
11/2021 | Upstack | Debt Financing | 0 |
8/2021 | Unchained Labs | Debt Financing | 0 |
5/2021 | Xtant Medical | Post-IPO Debt | 0 |
3/2021 | LendingPoint | Debt Financing | 0 |
5/2020 | Medexus Pharma | Post-IPO Debt | 0 |
1/2020 | Digital Reasoning | Series D | 0 |
12/2019 | Arboretum Investment Advisors, LLC. | Debt Financing | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|